Æȷοì
Andrea Anichini
Andrea Anichini
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
istitutotumori.mi.itÀÇ À̸ÞÀÏ È®ÀÎµÊ - ȨÆäÀÌÁö
Á¦¸ñ
Àοë
Àοë
¿¬µµ
Role of macrophage targeting in the antitumor activity of trabectedin
G Germano, R Frapolli, C Belgiovine, A Anselmo, S Pesce, M Liguori, ...
Cancer cell 23 (2), 249-262, 2013
8942013
Interleukin-12: biological properties and clinical application
M Del Vecchio, E Bajetta, S Canova, MT Lotze, A Wesa, G Parmiani, ...
Clinical Cancer Research 13 (16), 4677-4685, 2007
7332007
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study
A Necchi, A Anichini, D Raggi, A Briganti, S Massa, R Lucianò, ...
Journal of Clinical Oncology 36 (34), 3353-3360, 2018
5822018
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
G Parmiani, C Castelli, P Dalerba, R Mortarini, L Rivoltini, FM Marincola, ...
Journal of the National Cancer Institute 94 (11), 805-818, 2002
5512002
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
T Lakshmikanth, S Burke, TH Ali, S Kimpfler, F Ursini, L Ruggeri, ...
The Journal of clinical investigation 119 (5), 1251-1263, 2009
4052009
Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade
G Lo Russo, M Moro, M Sommariva, V Cancila, M Boeri, G Centonze, ...
Clinical Cancer Research 25 (3), 989-999, 2019
3842019
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
L Rivoltini, M Carrabba, V Huber, C Castelli, L Novellino, P Dalerba, ...
Immunological reviews 188 (1), 97-113, 2002
3732002
Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.
S Siena, M Di Nicola, M Bregni, R Mortarini, A Anichini, L Lombardi, ...
Experimental hematology 23 (14), 1463-1471, 1995
2981995
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
A Anichini, C Maccalli, R Mortarini, S Salvi, A Mazzocchi, P Squarcina, ...
The Journal of experimental medicine 177 (4), 989-998, 1993
2611993
BRAF alterations are associated with complex mutational profiles in malignant melanoma
M Daniotti, M Oggionni, T Ranzani, V Vallacchi, V Campi, D Di Stasi, ...
Oncogene 23 (35), 5968-5977, 2004
2432004
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide ¡¦
A Anichini, A Molla, R Mortarini, G Tragni, I Bersani, M Di Nicola, ...
The Journal of experimental medicine 190 (5), 651-668, 1999
2281999
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma
R Mortarini, A Piris, A Maurichi, A Molla, I Bersani, A Bono, C Bartoli, ...
Cancer Research 63 (10), 2535-2545, 2003
2202003
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
E Bajetta, M Del Vecchio, R Mortarini, R Nadeau, A Rakhit, L Rimassa, ...
Clinical cancer research: an official journal of the American Association ¡¦, 1998
2191998
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients
L Passoni, L Longo, P Collini, AML Coluccia, F Bozzi, M Podda, ...
Cancer research 69 (18), 7338-7346, 2009
2132009
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
M Sensi, G Nicolini, C Petti, I Bersani, F Lozupone, A Molla, C Vegetti, ...
Oncogene 25 (24), 3357-3364, 2006
2092006
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand
Y Kim, AM Lillo, SCJ Steiniger, Y Liu, C Ballatore, A Anichini, R Mortarini, ...
Biochemistry 45 (31), 9434-9444, 2006
2082006
Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma.
A Anichini, R Mortarini, C Maccalli, P Squarcina, K Fleischhauer, ...
Journal of immunology (Baltimore, Md.: 1950) 156 (1), 208-217, 1996
1751996
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells
E Yvon, M Del Vecchio, B Savoldo, V Hoyos, A Dutour, A Anichini, G Dotti, ...
Clinical Cancer Research 15 (18), 5852-5860, 2009
1712009
Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases
A Garofalo, RGS Chirivi, C Foglieni, R Pigott, R Mortarini, I Martin-Padura, ...
Cancer research 55 (2), 414-419, 1995
1651995
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed ¡¦
R Lupetti, P Pisarra, A Verrecchia, C Farina, G Nicolini, A Anichini, ...
The Journal of experimental medicine 188 (6), 1005-1016, 1998
1631998
ÇöÀç ½Ã½ºÅÛÀÌ ÀÛµ¿µÇÁö ¾Ê½À´Ï´Ù. ³ªÁß¿¡ ´Ù½Ã ½ÃµµÇØ ÁÖ¼¼¿ä.
ÇмúÀÚ·á 1–20